Join AlphaMaven

The Home Of Alternative Investments

Register For Free Learn More Create Investment Listing

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Alternative Investment Posts

Andrea Alms Video:  Money In Motion 160 - Pharma Q1 2025 Revenue Decline
Private Equity BrookDell Partners Views: 1

Andrea Alms Video: Money in Motion 160 - Pharma Q1 2025 Revenue Decline

TRANSCRIPT: Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. After fourth quarter 2024, in which revenues boomed throughout the biopharma industry, there were reversals for several drug makers. In Q1, which is the first three months of 2025. The companies that took the biggest hits were in the US, where there is considerable angst in the industry over ta


Member Posts:

Most popular| Most recent
AlphaMaven Crypto Traders Index
Crypto AlphaMaven Crypto Traders Index #Investment Update
AlphaMaven Cannabis Index
Cannabis AlphaMaven Cannabis Index #Investment Update
Quanterra Capital Management L.P. - AlphaMaven Performance Report
Hedge Fund Quanterra Capital Management L.P. #Investment Update
AlphaMaven Hedge Fund Index
Hedge Fund AlphaMaven Hedge Fund Index #Investment Update
New Lantern Hedged Equity Fund, LP -     May 2025 Factsheet
Hedge Fund New Lantern Hedged Equity Fund, LP #Investment Update #Commentary
New Lantern Investor Presentation - May 2025
Hedge Fund New Lantern Hedged Equity Fund, LP #Presentation
New Lantern Hedged Equity Fund - May 2025 Factsheet
Hedge Fund New Lantern Hedged Equity Fund, LP #Commentary
AlphaMaven Managed Futures Index
Managed Futures AlphaMaven Managed Futures Index #Investment Update
AlphaMaven Real Estate Index
Real Estate AlphaMaven Real Estate Index #Investment Update
AlphaMaven Private Equity Index
Private Equity AlphaMaven Private Equity Index #Investment Update
AlphaMaven Venture Capital Index
Venture Capital AlphaMaven Venture Capital Index #Investment Update
Camelot Event-Driven Fund Posts Its March 2025 Results
Hedge Fund Camelot Event-Driven Fund (EVDAX) #Investment Update
Camelot Event-Driven Fund Investor Presentation Q1 2025
Hedge Fund Camelot Event-Driven Fund (EVDAX) #Presentation
Tecumseh - AIR II Fund, LP Posts Its October 2024 Results
Hedge Fund Tecumseh - AIR II Fund, LP #Investment Update
Quanterra Capital Management L.P. Posts Its May 2025 Results
Hedge Fund Quanterra Capital Management L.P. #Investment Update
O'Brien Investment Group's Pecus Digital Assets Fund, LP - AlphaMaven Performance Report
Crypto Pecus Digital Assets Fund, LP #Investment Update
O'Brien Investment Group's Pecus Digital Assets Fund, LP Releases Its May 2025 Results
Crypto Pecus Digital Assets Fund, LP #Investment Update
Meteora Select Trading Opportunities, LP - AlphaMaven Performance Report
Hedge Fund Meteora Select Trading Opportunities, LP #Investment Update
Genio Primo (2L) Systematic Macro Program Releases Its May 2025 Results
Managed Futures Genio Primo (2L) Systematic Macro Program #Investment Update
Crawford Capital Partners, LP Releases Its May 2025 Performance
Hedge Fund Crawford Capital Partners, LP #Investment Update
RECEIVE FREE NEWSLETTER
View Member Posts Listings
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 158 - Micro Carrier Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 154 - Cell Therapy Manufacturing Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 160 - Pharma Q1 2025 Revenue Decline
- posted by: BrookDell Partners
Exome Worldwide Healthcare Partners Posts Its April 2025 Performance
- posted by: Worldwide Healthcare Partners
Exome's Emerging Markets Healthcare Strategy Posts Its April 2025 Results
- posted by: Emerging Markets Healthcare Partners Strategy
Andrea Alms Video:  Money In Motion 156 - Measles Vaccine Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 159 - Bitcoin Energy Mining
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 155 - Healthcare Professional Training Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 157 - Disruption In The Gene Cell Therapy Market
- posted by: BrookDell Partners
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates

Subscribe to our FREE DAILY newsletter

Please Select Industry Primary Role*
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.